Literature DB >> 33197333

Heparin-mediated dimerization of follistatin.

Ryan G Walker1, Chandramohan Kattamuri1, Erich J Goebel1, Fuming Zhang2,3, Michal Hammel4, John A Tainer5, Robert J Linhardt2,3, Thomas B Thompson1.   

Abstract

Heparin and heparan sulfate (HS) are highly sulfated polysaccharides covalently bound to cell surface proteins, which directly interact with many extracellular proteins, including the transforming growth factor-β (TGFβ) family ligand antagonist, follistatin 288 (FS288). Follistatin neutralizes the TGFβ ligands, myostatin and activin A, by forming a nearly irreversible non-signaling complex by surrounding the ligand and preventing interaction with TGFβ receptors. The FS288-ligand complex has higher affinity than unbound FS288 for heparin/HS, which accelerates ligand internalization and lysosomal degradation; however, limited information is available for how FS288 interactions with heparin affect ligand binding. Using surface plasmon resonance (SPR) we show that preincubation of FS288 with heparin/HS significantly decreased the association kinetics for both myostatin and activin A with seemingly no effect on the dissociation rate. This observation is dependent on the heparin/HS chain length where small chain lengths less than degree of polymerization 10 (dp10) did not alter association rates but chain lengths >dp10 decreased association rates. In an attempt to understand the mechanism for this observation, we uncovered that heparin induced dimerization of follistatin. Consistent with our SPR results, we found that dimerization only occurs with heparin molecules >dp10. Small-angle X-ray scattering of the FS288 heparin complex supports that FS288 adopts a dimeric configuration that is similar to the FS288 dimer in the ligand-bound state. These results indicate that heparin mediates dimerization of FS288 in a chain-length-dependent manner that reduces the ligand association rate, but not the dissociation rate or antagonistic activity of FS288.

Entities:  

Keywords:  Follistatin; activin; heparan sulfate; heparin; myostatin (GDF8); transforming growth factor beta

Mesh:

Substances:

Year:  2020        PMID: 33197333      PMCID: PMC7885052          DOI: 10.1177/1535370220966296

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  50 in total

1.  Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins.

Authors:  Yisrael Sidis; Abir Mukherjee; Henry Keutmann; Anne Delbaere; Miyuki Sadatsuki; Alan Schneyer
Journal:  Endocrinology       Date:  2006-04-20       Impact factor: 4.736

2.  Accurate SAXS profile computation and its assessment by contrast variation experiments.

Authors:  Dina Schneidman-Duhovny; Michal Hammel; John A Tainer; Andrej Sali
Journal:  Biophys J       Date:  2013-08-20       Impact factor: 4.033

3.  Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity.

Authors:  R Ruppert; E Hoffmann; W Sebald
Journal:  Eur J Biochem       Date:  1996-04-01

4.  Prediction of heparin binding sites in bone morphogenetic proteins (BMPs).

Authors:  Neha S Gandhi; Ricardo L Mancera
Journal:  Biochim Biophys Acta       Date:  2012-07-21

5.  Characterizing flexible and intrinsically unstructured biological macromolecules by SAS using the Porod-Debye law.

Authors:  Robert P Rambo; John A Tainer
Journal:  Biopolymers       Date:  2011-04-20       Impact factor: 2.505

Review 6.  Activin receptor signaling.

Authors:  Yumiko Abe; Takashi Minegishi; Peter C K Leung
Journal:  Growth Factors       Date:  2004-06       Impact factor: 2.511

7.  The structure of FSTL3.activin A complex. Differential binding of N-terminal domains influences follistatin-type antagonist specificity.

Authors:  Robin Stamler; Henry T Keutmann; Yisrael Sidis; Chandramohan Kattamuri; Alan Schneyer; Thomas B Thompson
Journal:  J Biol Chem       Date:  2008-09-02       Impact factor: 5.157

8.  Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice.

Authors:  Masashi Nakatani; Yuka Takehara; Hiromu Sugino; Mitsuru Matsumoto; Osamu Hashimoto; Yoshihisa Hasegawa; Tatsuya Murakami; Akiyoshi Uezumi; Shin'ichi Takeda; Sumihare Noji; Yoshihide Sunada; Kunihiro Tsuchida
Journal:  FASEB J       Date:  2007-09-24       Impact factor: 5.191

9.  Bone morphogenetic protein (BMP) ligands and receptors in bovine ovarian follicle cells: actions of BMP-4, -6 and -7 on granulosa cells and differential modulation of Smad-1 phosphorylation by follistatin.

Authors:  Claire Glister; C Fred Kemp; Philip G Knight
Journal:  Reproduction       Date:  2004-02       Impact factor: 3.906

10.  Structural basis for potency differences between GDF8 and GDF11.

Authors:  Ryan G Walker; Magdalena Czepnik; Erich J Goebel; Jason C McCoy; Ana Vujic; Miook Cho; Juhyun Oh; Senem Aykul; Kelly L Walton; Gauthier Schang; Daniel J Bernard; Andrew P Hinck; Craig A Harrison; Erik Martinez-Hackert; Amy J Wagers; Richard T Lee; Thomas B Thompson
Journal:  BMC Biol       Date:  2017-03-03       Impact factor: 7.431

View more
  1 in total

1.  Universally Accessible Structural Data on Macromolecular Conformation, Assembly, and Dynamics by Small Angle X-Ray Scattering for DNA Repair Insights.

Authors:  Naga Babu Chinnam; Aleem Syed; Kathryn H Burnett; Greg L Hura; John A Tainer; Susan E Tsutakawa
Journal:  Methods Mol Biol       Date:  2022
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.